Related Experiment Videos
Therapy of hepatitis C: other options
1Division of Digestive Disease and Nutrition and the Liver-Biliary-Pancreatic Center, University of Massachusetts Medical Center, Worcester, USA.
Hepatology (Baltimore, Md.)
|September 26, 1997
Summary
Reducing liver iron stores, often with phlebotomy, can improve alpha interferon treatment response in chronic hepatitis C patients. This approach enhances both biochemical and virological outcomes, especially in previously untreated individuals.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Standard alpha interferon therapy for chronic hepatitis C has suboptimal efficacy.
- Hepatic iron accumulation is linked to reduced response rates to alpha interferon.
- Oxidative stress and decreased glutathione levels are associated with chronic hepatitis C and hepatic iron.
Framework:
- Investigating iron reduction (e.g., phlebotomy) as an adjunct to alpha interferon therapy.
- Evaluating the impact of N-acetyl cysteine, a sulfhydryl donor, on interferon response.
- Exploring other immunomodulators like thymosin alpha-1 and agents such as amantadine and ursodiol.
Implementation:
- Therapeutic phlebotomy for iron reduction has shown biochemical improvements but not consistently virological ones.
- Combining iron reduction with alpha interferon has demonstrated improved responsiveness in some studies, notably increasing sustained response rates from 5% to 29% in treatment-naive patients.
- N-acetyl cysteine administration has been reported to enhance interferon response in chronic hepatitis C.
Implications:
- Iron reduction strategies may enhance the effectiveness of current and future hepatitis C therapies.
- Addressing oxidative stress and exploring multidrug combinations, including protease and RNA polymerase inhibitors, represent promising future therapeutic directions.
- Further research into novel agents and combination therapies is crucial for improving outcomes in chronic hepatitis C management.